1. Immunology/Inflammation
    GPCR/G Protein
  2. FLAP
    Leukotriene Receptor
  3. Veliflapon

Veliflapon (Synonyms: BAY X 1005; DG-031)

Cat. No.: HY-14165 Purity: >99.0%
Handling Instructions

Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4.

For research use only. We do not sell to patients.

Veliflapon Chemical Structure

Veliflapon Chemical Structure

CAS No. : 128253-31-6

Size Price Stock
10 mM * 1 mL in DMSO USD 382 Ask For Quote & Lead Time
5 mg USD 480 Ask For Quote & Lead Time
10 mg USD 820 Ask For Quote & Lead Time

* Please select Quantity before adding items.

Top Publications Citing Use of Products

View All Leukotriene Receptor Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review


Veliflapon (BAY X 1005; DG-031) is an orally active and selective 5-lipoxygenase activating protein (FLAP) inhibitor[1]. Veliflapon inhibits the synthesis of the leukotrienes B4 and C4[2].

IC50 & Target[1][2]





In Vitro

Veliflapon (BAY X 1005; DG-031) effectively inhibits the synthesis of LTB4 in A23187-stimulated leukocytes from rats, mice and humans (IC50s of 0.026, 0.039 and 0.22 μM, respectively) as well as the formation of LTC4 (IC50 of 0.021 μM) in mouse peritoneal macrophages stimulated with opsonized zymosan[3].

In Vivo

Veliflapon (BAY X 1005; DG-031; diet; 18.8 mg/kg/day for 16 weeks ) inhibits atherogenesis[4].
Veliflapon after topical (18 μg/ear) and oral (48.7 mg/kg) administration has antiedematous effects in the arachidonic acid-induced mouse ear inflammation test[4].
Veliflapon is potent (11.8 and 6.7 mg/kg p.o. at 1 and 5 hours, respectively) and has a long duration of action (ED40 of 16 hours, 70 mg/kg p.o.) in the rat whole blood ex vivo leukotriene B4 inhibition assay[4].

Animal Model: Female apoE/LDLR-DKO mouse model[4]
Dosage: 18.8 mg/kg
Administration: Diet; per day during 16 weeks
Result: Inhibited atherogenesis.
Clinical Trial
Molecular Weight







O=C(O)[[email protected]](C1CCCC1)C(C=C2)=CC=C2OCC3=NC4=CC=CC=C4C=C3


Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Purity: >99.0%

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2


VeliflaponBAY X 1005DG-031BAY X1005BAY X-1005DG031DG 031FLAPLeukotriene Receptor5-lipoxygenase-activating protein5-LO activating proteinorallyactiveleukotrienesB4C45-lipoxygenaseactivatingproteinarachidonicacidmetabolismatherogenesisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product name:
Cat. No.:
MCE Japan Authorized Agent: